Key result
Atrial high rate episodes detected by cardiac implantable electronic devices were independently associated with an increased risk of thromboembolism (HR 3.40) and death (HR 3.47).
Why the study?
Although AHREs detected by CIEDs are associated with stroke, the impact of AHRE on improving stroke risk stratification schemes remains uncertain.
Does the presence of atrial high rate episodes (AHREs) increase the risk of thromboembolism or all-cause death in patients with dual-chamber cardiac implantable electronic devices?
Cohort (n=856)
No
Does the presence of atrial high rate episodes (AHREs) increase the risk of thromboembolism or all-cause death in patients with dual-chamber cardiac implantable electronic devices?
Effect estimate: HR 3.40 (95% CI 1.38-8.37)
Absolute Event Rate: 2.6% vs 0.9%
p-value: p=0.01
Atrial high rate episodes detected by cardiac implantable electronic devices are independently associated with an increased risk of thromboembolism and all-cause death, and their addition to clinical risk scores improves risk discrimination.
AHREs may identify higher-risk CIED patients for closer monitoring; extends prior associations but leaves anticoagulation decisions open pending trials.
Atrial high rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of stroke. However, the impact of AHRE on improving stroke risk stratification scheme remains uncertain. The purpose of this study was to assess the impact of AHRE on prognosis in relation with cardiovascular events and risk stratification. A total of 856 consecutive patients who had dual-chamber CIEDs implanted were retrospectively analyzed. To detect AHREs, they were monitored for 6 months after CIEDs’ implantation and were followed for a mean of 4.0 years for clinical outcomes such as thromboembolism or death. Overall, 125 (14.6%) of patients developed AHREs within the first 6 months (median age 72.0 years, 39.3% female). Patients with AHREs had a high rate of thromboembolism (2.6%/year) and mortality (3.0%/year). On multivariate analysis, AHRE was significantly associated with increased risk of thromboembolism [hazard ratio (HR) 3.40; 95% confidence interval (CI) 1.38–8.37, P = 0.01] and death (HR 3.47; 95% CI 1.51–7.95; P < 0.01). The predictive abilities of the CHADS2 and CHA2DS2-VASc scores were modest, with no significant improvements by adding AHRE to those scores. However, the integrated discrimination improvement and net reclassification improvement showed that the addition of AHRE to the CHADS2 and CHA2DS2-VASc scores statistically improved their predictive ability for the composite outcome. AHRE was an independent factor associated with increased risk of clinical outcomes. The addition of AHRE to the clinical risk scores significantly improved discrimination for thromboembolism or death.
No takes yet. Share an insight, caveat, or question.
Miyazawa et al. (2019) conducted a cohort in Patients with cardiac implantable electronic devices (CIEDs) (n=856). Atrial high rate episodes (AHREs) vs. No AHREs was evaluated on Thromboembolism (HR 3.40, 95% CI 1.38-8.37, p=0.01). Atrial high rate episodes detected by cardiac implantable electronic devices were independently associated with an increased risk of thromboembolism (HR 3.40) and death (HR 3.47).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: